Pharma files complaint to stop Italy off-label law
Europe’s pharma and biotech companies are taking action to stop a new Italian law promoting off-label use of drugs, saying the measure is aimed solely at saving money.
Read MoreAuthor: Kevin Grogan
Worldwide HCV treatment within sight at affordable prices
A new academic study says it is feasible that global hepatitis C treatment could be achieved if the manufacturing and monitoring costs of the new generation of drugs “were minimised in the same way as was done with HIV”, by lifting patents to allow them to made by generics firm.
Read MoreSouth Australia stakes claim as health hub
Heavyweights in the pharmaceutical world have met with other stakeholders in Adelaide to explore investment and growth for the South Australian healthcare sector.
Read MoreEurope okays J&J’s Velcade for mantle cell lymphoma
European regulators have expanded the label on Johnson & Johnson’s multiple myeloma drug Velcade to cover mantle cell lymphoma.
Read MoreFourth US approval for Roche eye blockbuster Lucentis
The US Food and Drug Administration has expanded approval on Roche’s eye blockbuster Lucentis.
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
